Project leaders

Prof. Dr. Stefan Endres

Coordinator of IMMUTRAIN | Director of the Division of Clinical Pharmacology | Ludwig-Maximilians-Universität München | Supervisor of ESR1 and ESR2 within the workpackage 1: Combination of antibodies with adoptive T cell transfer

PD Dr. Sebastian Kobold

Scientific Coordinator of IMMUTRAIN | Group Leader of Immunopharmacology | Division of Clinical Pharmacology | Ludwig-Maximilians-Universität München | Supervisor of ESR1 and ESR2 within the workpackage 1: Combination of antibodies with adoptive T cell transfer

Prof. Robert Rees

Director of the Van Geest Cancer Research Centre | Nottingham Trent University | Supervisor of ESR 3 within the work package 1: Combination of antibodies with adoptive T cell transfer

Tarik Regad DVetM, MSc, MRes, PhD, FHEA

Senior Research Fellow; 
The John van Geest Cancer Research Centre; Nottingham Trent University; Co supervisor of ESR 3; WP 1

Prof. Dr. Max Schnurr

Group Leader Cancer Vaccine Lab | Division of Clinical Pharmacology | Ludwig-Maximilians-Universität München | Supervisor of ESR13 within the work package 4: Target discovery and validation for antibody combination therapies

Prof. Gosse Adema

Department of Radiation Oncology Radiotherapy & OncoImmunology Laboratory | Radboud Institute for Molecular Life Sciences | Radboud University Medical Centre | Supervisor of ESR9 within the work package 3: Combination of antibodies with dendritic cell therapy

Prof. Dr. Karl-Peter Hopfner

Group Leader of Structural Molecular Biology Gene Center | Ludwig-Maximilians-Universität München | Supervisor of ESR6 within the work package 2: New formulations and combinations of antibodies to activate immune cells

Prof. Carole Bourquin

Group Leader Pharmacology | Université de Genève| Supervisor of ESR15 within the work package 4: Target discovery and validation for antibody combination therapies

Dr. Claudio Sustmann

Head of Dpt. for Molecular Design & Engineering Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Munich, Large Molecule Research | Supervisor of ESR7 within the work package 2: New formulations of antibodies to activate immune cells

Prof. Maria Rescigno

Group Leader Mucosal immunology and microbiota Unit – Humanitas Research Hospital

Dr. Maria S. Soengas

Head of the Melanoma Group | Spanish National Cancer Research Centre | Supervisor of ESR14 and ESR15 within the work package 4: Target discovery and validation for antibody combination therapies | Co-founder of BiOncotech

Assoc. Prof. Patrizia Stoitzner

Head of the Langerhans Cell Research Lab | Department of Dermatology,Venereology & Allergology | Medical University of Innsbruck | Supervisor of ESR 10 within the work package 3: Combination of antibodies with dendritic cell therapy

Prof. Per Thor Straten

Director of the Center for Cancer Immunotherapy | University Hospital Herlev, Region Hovedstaden | Supervisor of ESR4 and ESR5 within the work package 1: Combination of antibodies with adoptive T cell transfer

Prof. Laurence Zitvogel

Group Leader of Tumour immunology and immunotherapy of cancer | Institut Gustave Roussy | Supervisor of ESR11 within the work package 4: Target discovery and validation for antibody combination therapies

Prof. Graham Ball

Head of CompanyDX ltd - UK

Dr. Christian Klein

Head Oncology Programs & Department Head Cancer - Roche Innovation Center Zurich - CH

Dr. Stefan Strobl

Head of Small Molecules - BioNTech Smalll Molecules - DE

Prof. Hans-Martin Jaeck

Professor of Immunology Division of Molecular Immunology Nikolaus-Fiebiger-Zentrum University of Erlangen-Nürnberg - DE